What shareholders can do to beat the market with Agile Therapeutics Inc. (AGRX) stock

In the latest session, Agile Therapeutics Inc. (NASDAQ: AGRX) closed at $0.19 down -8.57% from its previous closing price of $0.21. In other words, the price has decreased by -$0.0180 from its previous closing price. On the day, 1184538 shares were traded. AGRX stock price reached its highest trading level at $0.2135 during the session, while it also had its lowest trading level at $0.1879.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.



For a deeper understanding of Agile Therapeutics Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.30. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

On November 29, 2018, Maxim Group started tracking the stock assigning a Buy rating and target price of $3.Maxim Group initiated its Buy rating on November 29, 2018, with a $3 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 26 when ALTOMARI ALFRED bought 50,000 shares for $0.45 per share. The transaction valued at 22,500 led to the insider holds 64,343 shares of the business.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 0.97 while its Price-to-Book (P/B) ratio in mrq is 1.13.

Stock Price History:

Over the past 52 weeks, AGRX has reached a high of $29.60, while it has fallen to a 52-week low of $0.19. The 50-Day Moving Average of the stock is 0.2845, while the 200-Day Moving Average is calculated to be 3.3194.

Shares Statistics:

For the past three months, AGRX has traded an average of 1.32M shares per day and 1.6M over the past ten days. A total of 37.00M shares are outstanding, with a floating share count of 36.81M. Insiders hold about 0.20% of the company’s shares, while institutions hold 5.70% stake in the company. Shares short for AGRX as of Oct 13, 2022 were 1.22M with a Short Ratio of 1.58M, compared to 1.47M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 3.14% and a Short% of Float of 3.14%.

Earnings Estimates

There are 2 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.29 for the current quarter, with a high estimate of -$0.29 and a low estimate of -$0.3, while EPS last year was -$8. The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.27 and low estimates of -$0.27.

Analysts are recommending an EPS of between -$2.15 and -$2.17 for the fiscal current year, implying an average EPS of -$2.16. EPS for the following year is -$0.62, with 2 analysts recommending between -$0.42 and -$0.83.

Revenue Estimates

A total of 2 analysts believe the company’s revenue will be $2.33M this quarter.It ranges from a high estimate of $2.46M to a low estimate of $2.2M. As of the current estimate, Agile Therapeutics Inc.’s year-ago sales were $1.29M, an estimated increase of 81.00% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $3.12M, an increase of 106.10% over than the figure of $81.00% in the same quarter last year. There is a high estimate of $3.16M for the next quarter, whereas the lowest estimate is $3.08M.

A total of 2 analysts have provided revenue estimates for AGRX’s current fiscal year. The highest revenue estimate was $9.51M, while the lowest revenue estimate was $8.89M, resulting in an average revenue estimate of $9.2M. In the same quarter a year ago, actual revenue was $4.1M, up 124.30% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $22.24M in the next fiscal year. The high estimate is $24.22M and the low estimate is $20.26M. The average revenue growth estimate for next year is up 141.70% from the average revenue estimate for this year.